News

Silo Pharma and Allucent Collaborate on PTSD Drug Development

Silo Pharma and Allucent Collaborate on PTSD Drug Development

Silo Pharma and Allucent Join Forces for PTSD Treatment

Silo Pharma, Inc. (NASDAQ: SILO), a groundbreaking biopharmaceutical company, has recently made a strategic decision that may significantly impact the treatment landscape for PTSD. The company has partnered with Allucent, a renowned global clinical research organization, to bolster its efforts in developing SPC-15, an innovative intranasal therapeutic specifically designed for those suffering from post-traumatic stress disorder.

Understanding the Importance of the Partnership

This collaboration marks a pivotal step forward for Silo Pharma as it gears up for its planned investigational new drug application (IND) submission to the FDA. With preparations underway, the company anticipates submitting its IND in the near future, paving the way for the first-in-human (FIH) Phase 1 clinical trial. The insights and expertise provided by Allucent will be instrumental in shaping the clinical development strategy for SPC-15.

“Partnering with Allucent represents a significant advancement in bringing our unique therapeutic to the forefront,” expressed Silo's CEO, Eric Weisblum. He emphasized the importance of conducting rigorous dose-ranging studies to ascertain SPC-15's pharmacokinetics and safety profile, with the ultimate goal of meeting the stringent standards set by the FDA for clinical trials.

The Path to FDA Approval

Silo Pharma is set on a clear course toward regulatory approval through the FDA's 505(b)(2) accelerated pathway. This strategic move could expedite the timeline for bringing artificial therapies to market, particularly for conditions that have long been underserved like PTSD. Upcoming data from toxicology studies and drug-device investigations are poised to underpin the safety and efficacy of SPC-15. The results are expected in early 2026, which could further inform the company’s approach.

Broader Mission of Silo Pharma

At the heart of Silo Pharma's mission is the commitment to addressing inadequately treated conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's diverse portfolio also includes other promising candidates, such as SP-26 for fibromyalgia and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Collaborations with leading universities and state-of-the-art laboratories ensure that Silo remains at the cutting edge of biopharmaceutical innovation.

The Vision Behind Allucent

Allucent's role in this partnership is critical. With a rich history spanning over three decades, Allucent specializes in navigating the complex regulatory landscape of drug development. Their seasoned team of experts, including former regulators and scientists, is poised to deliver valuable insights to support Silo's clinical goals. By working closely with biopharmaceutical and government sectors worldwide, Allucent aims to expedite the introduction of new therapies that can transform patient lives.

Continuing the Quest for Innovation

As Silo Pharma prepares for the next stages of this exciting journey, the collaboration with Allucent signifies a unified commitment to tackling one of the most challenging aspects of mental health treatment today. SPC-15 represents a beacon of hope for those afflicted by PTSD—a testament to the importance of innovation in healthcare.

Frequently Asked Questions

What is SPC-15?

SPC-15 is an intranasal therapeutic being developed by Silo Pharma for the treatment of post-traumatic stress disorder (PTSD).

What does the partnership with Allucent involve?

The partnership with Allucent focuses on supporting Silo Pharma's final preparations for the FDA IND submission and subsequent clinical trials for SPC-15.

When is the IND submission expected?

Silo Pharma expects to submit the IND in the near future, with clinical trials following FDA approval.

How does Silo Pharma approach drug development?

Silo Pharma emphasizes addressing underserved conditions and works with leading academic institutions to drive its innovative research efforts.

What is the expected timeline for trial results?

Data from preclinical studies related to SPC-15 is anticipated in early 2026, providing insights into its safety and efficacy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 59

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 68

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 114

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 114

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 71

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 57

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 95

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Sanoma Corporation's Recent Share Buyback Explained

Updated Category News Views 173

Insights into Sanoma Corporation's Share Buyback Activity Sanoma Corporation has conducted a significant share buyback, underscoring its commitment to enhancing shareholder value. These transactions were announced through a stock exchange release, giving investors an insightful look into the company's market activities. Details of the Buyback Transaction On a noteworthy...

Continue Reading
Finland's Real Estate Market Thrives in 2025: Key Insights

Updated Category News Views 248

The Resurgence of Finland's Real Estate Market Finland's real estate market is experiencing an inspiring recovery, marked by increasing transaction volumes and growing investment liquidity. This positive trend not only showcases renewed confidence among local investors but also reflects heightened interest from international players in the Finnish market. Analysts predict...

Continue Reading
Investors Alert: Join the Fight for Justice with aTyr Pharma

Updated Category News Views 190

Understanding the aTyr Pharma Situation Investors of aTyr Pharma Inc. are facing a challenging and distressing time following recent revelations regarding the company’s performance. The company is known for its innovative approaches in the realm of pharmaceuticals and has garnered significant attention in the stock market. However, the recent downturn in share value has...

Continue Reading
Fly Play hf. Reports Q2 Losses Amid External Challenges

Updated Category News Views 143

Profit Warning for Fly Play hf. Recently, Fly Play hf. shared concerns regarding its upcoming Q2 2025 interim financial report. The company anticipates that their results will fall short of last year’s performance and internal expectations. A net loss of around USD 16 million is projected for this quarter, compared to a loss of USD 10 million during the same period last...

Continue Reading
Olin Corporation Faces Challenges Amid Earnings Report

Updated Category News Views 85

Olin Corporation Reports Disappointing Third Quarter Earnings Olin Corporation (NYSE: OLN) recently announced its earnings for the third quarter of 2024, revealing significant challenges that led to a 14% drop in its stock price. This downturn was driven primarily by the fallout from Hurricane Beryl and a decline in demand within its ammunition division. Financial...

Continue Reading